In terms of recent activity, the company last year acquired Elios Vision, a glaucoma therapy developer. The Elios procedure uses an excimer laser to treat glaucoma in conjunction with cataract surgery without implants. Bausch + Lomb believes the deal enhances its glaucoma portfolio which already features pharmaceutical and surgical approaches.
Bausch + Lomb won’t sell after engaging with potential buyers
Bausch + Lomb announced today that, after engagement with potential buyers, it has no immediate plan to sell.
At the end of 2024, the company issued a statement outlining its plans for a potential separation from parent company Bausch Health.
The Vaughan, Ontario-based eye care company announced this in response to a request from the Canadian Investment Regulatory Organization (CIRO) related to stock volatility and market rumors. Bausch + Lomb stock trades on the New York Stock Exchange and Toronto Stock Exchange.
“Taking Bausch + Lomb private with a third-party buyer was one of several options being explored to complete a full separation from Bausch Health Companies Inc,” the company said in a statement. “After engagement with potential buyers, that process is complete, and will not result in a transaction at this time.
“Full separation remains the goal. Bausch + Lomb continues to operate as its own entity and execute on its strategies and business plan. The company, which raised 2024 revenue guidance on Oct. 30, will report fourth-quarter and full-year 2024 earnings on February 19, in addition to providing guidance for the 2025 fiscal year.”